

# Karla V Ballman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4546207/publications.pdf>

Version: 2024-02-01

242  
papers

26,702  
citations

13827

67  
h-index

6282

158  
g-index

251  
all docs

251  
docs citations

251  
times ranked

27609  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Feasibility of Radiation Therapy after Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. International Journal of Radiation Oncology Biology Physics, 2022, 112, 636-642.	0.4	6
2	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	0.8	62
3	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS216-TPS216.	0.8	2
4	Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Questionnaire. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2022, , .	0.5	1
5	Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clinical Cancer Research, 2022, 28, 2579-2586.	3.2	4
6	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 311-326.	1.8	3
7	Abstract 494: Role of age, BMI, and tumor subtype in racial/ethnic disparities in breast cancer survival: A pooled analysis of four Alliance adjuvant clinical trials. Cancer Research, 2022, 82, 494-494.	0.4	0
8	Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance).. Journal of Clinical Oncology, 2022, 40, 505-505.	0.8	2
9	Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).. Journal of Clinical Oncology, 2022, 40, 4562-4562.	0.8	0
10	Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance) Tj ETQq0 0 0 rgBTQ@verlock 10 Tf 50 3	0.8	0
11	Phase II study of KNO46 in patients with thymic carcinoma who failed immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, TPS8607-TPS8607.	0.8	1
12	Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).. Journal of Clinical Oncology, 2022, 40, 4521-4521.	0.8	0
13	MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	0
14	A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701).. Journal of Clinical Oncology, 2022, 40, TPS4615-TPS4615.	0.8	7
15	CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro-Oncology, 2021, 23, 457-467.	0.6	58
16	SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer, 2021, 127, 1301-1310.	2.0	20
17	Extrapolation of ACOSOG Z0011 trial resultsâ€”A survey of breast cancer providers. Breast Journal, 2021, 27, 537-542.	0.4	2
18	Randomized comparison of the clinical Outcome of single versus Multiple Arterial grafts: Quality of Life (ROMA:QOL) â€” Rationale and Study Protocol. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	1.8	0

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). <i>Breast Cancer Research and Treatment</i> , 2021, 188, 477-487.	1.1	5
20	Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort. <i>Respiratory Research</i> , 2021, 22, 126.	1.4	14
21	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	0.7	22
22	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5095-TPS5095.	0.8	0
23	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 436-437.	0.7	0
24	A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS595-TPS595.	0.8	1
25	P10015/SARCO33: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11503-11503.	0.8	6
26	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. <i>Communications Biology</i> , 2021, 4, 785.	2.0	3
27	FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 30-30.	0.6	0
28	Posterior left pericardiectomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. <i>Lancet, The</i> , 2021, 398, 2075-2083.	6.3	51
29	Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARCO21) trial. <i>Journal of Geriatric Oncology</i> , 2020, 11, 463-469.	0.5	7
30	Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 255-260.	0.4	22
31	Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). <i>Journal of Geriatric Oncology</i> , 2020, 11, 107-113.	0.5	38
32	25. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF NCCTG N107C/CEC.3 AND N0574 (ALLIANCE) RANDOMIZED CLINICAL TRIALS. <i>Neuro-Oncology Advances</i> , 2020, 2, ii4-ii4.	0.4	0
33	Association of Radial Artery Graft vs Saphenous Vein Graft With Long-term Cardiovascular Outcomes Among Patients Undergoing Coronary Artery Bypass Grafting. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 179.	3.8	118
34	Increased airway iron parameters and risk for exacerbation in COPD: an analysis from SPIROMICS. <i>Scientific Reports</i> , 2020, 10, 10562.	1.6	14
35	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARCO24 Study. <i>Oncologist</i> , 2020, 25, e1655-e1662.	1.9	13
36	Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 714-717.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 4650-4661.	0.7	13
38	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	0.5	21
39	Guidelines for Statistical Reporting in Medical Journals. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1722-1726.	0.5	10
40	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , 2020, 11, 5549.	5.8	76
41	Prognostic value of the SPOP mutant genomic subclass in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 418-422.	0.8	8
42	Clinical Significance of Circulating Tumor Cells in Hormone Receptor-Positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. <i>Clinical Cancer Research</i> , 2020, 26, 4911-4920.	3.2	14
43	Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 429-436.	1.1	6
44	Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. <i>Neuro-Oncology</i> , 2020, 22, 830-837.	0.6	27
45	Challenges Faced by Medical Journals During the COVID-19 Pandemic. <i>Journal of Clinical Oncology</i> , 2020, 38, 2206-2207.	0.8	35
46	CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577,) <i>Journal of Clinical Oncology</i> , 2020, 38, 2206-2207.	0.6	0
47	Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort. <i>JCI Insight</i> , 2020, 5, .	2.3	37
48	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5560-5560.	0.8	9
49	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS5100-TPS5100.	0.8	6
50	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 114-114.	0.8	17
51	Efficacy of osimertinib against EGFRVIII+ glioblastoma. <i>Oncotarget</i> , 2020, 11, 2074-2082.	0.8	37
52	ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600.	0.8	1
53	PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS760-TPS760.	0.8	2
54	CTNI-01. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS. <i>Neuro-Oncology</i> , 2020, 22, ii40-ii41.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 920-927.	1.3	67
56	Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. <i>Supportive Care in Cancer</i> , 2019, 27, 495-503.	1.0	51
57	Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. <i>JAMA Surgery</i> , 2019, 154, 800.	2.2	58
58	Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance). <i>Annals of Surgical Oncology</i> , 2019, 26, 4213-4221.	0.7	3
59	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 7-18.	1.3	195
60	Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 174-182.	0.4	30
61	Temporal Trends in the Use of Acute Recanalization Therapies for Ischemic Stroke in Patients with Cancer. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2255-2261.	0.7	11
62	ACTR-07. LONG-TERM OUTCOMES FROM INTERGROUP NCCTG 86-72-51 (ALLIANCE): FINAL REPORT OF A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF HIGH DOSE VERSUS LOW DOSE RADIATION IN ADULT SUPRATENTORIAL LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi13-vi14.	0.6	0
63	The RADial artery International Alliance (RADIAL) extended follow-up study: rationale and study protocol. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 1025-1030.	0.6	7
64	A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 43-51.	3.2	177
65	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
66	Reply to "Can Patients with Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? Response to the Preliminary Alliance 11102 Trial Report". <i>Annals of Surgical Oncology</i> , 2019, 26, 702-702.	0.7	0
67	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 4503-4503.	0.8	35
68	PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4596-TPS4596.	0.8	5
69	Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 272-272.	0.8	8
70	Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS504-TPS504.	0.8	16
71	Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS339-TPS339.	0.8	1
72	Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients (pts) receiving letrozole (Let) or Let plus bevacizumab (Bev): CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2019, 37, 1049-1049.	0.8	0

#	ARTICLE	IF	CITATIONS
73	ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS599-TPS599.	0.8	2
74	Outcome of patients with refractory malignant peripheral nerve sheath tumors (MPNST) enrolled on phase 2 trials.. Journal of Clinical Oncology, 2019, 37, e22534-e22534.	0.8	0
75	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-Oncology, 2018, 20, 546-556.	0.6	93
76	Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). American Journal of Roentgenology, 2018, 210, 669-676.	1.0	47
77	Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer—Reply. JAMA - Journal of the American Medical Association, 2018, 319, 306.	3.8	3
78	The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). Journal of Geriatric Oncology, 2018, 9, 221-227.	0.5	14
79	National trends in management of localized prostate cancer: A population based analysis 2004–2013. Prostate, 2018, 78, 512-520.	1.2	49
80	An omnibus test for differential distribution analysis of microbiome sequencing data. Bioinformatics, 2018, 34, 643-651.	1.8	69
81	Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. Journal of Urology, 2018, 199, 947-953.	0.2	47
82	Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research and Treatment, 2018, 171, 325-334.	1.1	3
83	Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research, 2018, 20, 52.	2.2	12
84	Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature Medicine, 2018, 24, 1015-1023.	15.2	447
85	The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Annals of Surgical Oncology, 2018, 25, 2858-2866.	0.7	41
86	Circulating RIPK3 levels are associated with mortality and organ failure during critical illness. JCI Insight, 2018, 3, .	2.3	32
87	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. Journal of Clinical Oncology, 2018, 36, 10066-10066.	0.8	2
88	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. Journal of Clinical Oncology, 2018, 36, 11505-11505.	0.8	3
89	SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.. Journal of Clinical Oncology, 2018, 36, TPS11588-TPS11588.	0.8	16
90	Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial.. Journal of Clinical Oncology, 2018, 36, 513-513.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Subgroup analysis of elderly patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.. Journal of Clinical Oncology, 2018, 36, 11575-11575.	0.8	0
92	Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Research and Treatment, 2017, 163, 391-398.	1.1	16
93	Brachytherapy improves outcomes in young men (â‰¥60Âyears) with prostate cancer: A SEER analysis. Brachytherapy, 2017, 16, 323-329.	0.2	6
94	The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecologic Oncology, 2017, 144, 159-166.	0.6	30
95	Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, 469-474.	0.6	34
96	IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clinical Cancer Research, 2017, 23, 4203-4211.	3.2	8
97	Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trialâ€™ rationale and study protocolâ€™. European Journal of Cardio-thoracic Surgery, 2017, 52, 1031-1040.	0.6	136
98	Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA - Journal of the American Medical Association, 2017, 318, 918.	3.8	1,166
99	Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1173-1178.	0.4	69
100	Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECA-3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1049-1060.	5.1	840
101	Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Annals of Surgery, 2017, 266, 667-676.	2.1	62
102	National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the US Preventive Services Task Force Guidelines Against Prostate-Specific Antigen Screening. JAMA Surgery, 2017, 152, 192.	2.2	41
103	Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial. Journal of Urology, 2017, 197, 1014-1019.	0.2	20
104	Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. Journal of Urology, 2017, 197, 363-368.	0.2	20
105	Study of the Impact of the Location of a Perforator in the Perfusion of a Perforator Flap: The Concept of â€™Angle of Perfusionâ€™. Journal of Reconstructive Microsurgery, 2017, 33, 049-058.	1.0	6
106	Patient-Reported Outcomes after Laparoscopic Ventral Hernia Repair. American Surgeon, 2016, 82, 550-556.	0.4	6
107	Reply to M. Minden. Journal of Clinical Oncology, 2016, 34, 1703-1704.	0.8	1
108	Social support and its implications in older, earlyâ€™stage breast cancer patients in CALGB 49907 (Alliance) Tj ETQq000 rgBT/Overlock	1.0	18

#	ARTICLE	IF	CITATIONS
109	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. <i>Annals of Surgery</i> , 2016, 264, 413-420.	2.1	392
110	Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. <i>Journal of Urology</i> , 2016, 196, 1047-1052.	0.2	49
111	Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. <i>Cancer Research</i> , 2016, 76, 3702-3710.	0.4	51
112	Pragmatic study designs for older adults with cancer: Report from the U13 conference. <i>Journal of Geriatric Oncology</i> , 2016, 7, 234-241.	0.5	40
113	Survival Implications of Variation in the Thoroughness of Pathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance). <i>Annals of Thoracic Surgery</i> , 2016, 102, 363-369.	0.7	55
114	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). <i>Breast Cancer Research and Treatment</i> , 2016, 159, 109-118.	1.1	47
115	Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 401.	3.8	1,225
116	Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0â€“T4, N1â€“N2) Who Receive Neoadjuvant Chemotherapy. <i>Annals of Surgery</i> , 2016, 263, 802-807.	2.1	351
117	A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. <i>Annals of Surgical Oncology</i> , 2016, 23, 2438-2445.	0.7	95
118	Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 493-502.	0.4	33
119	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62
120	Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1007-1007.	0.8	9
121	Impact of demographics on human gut microbial diversity in a US Midwest population. <i>PeerJ</i> , 2016, 4, e1514.	0.9	61
122	Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2029-2029.	0.8	0
123	Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10047-10047.	0.8	0
124	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831. <i>Breast Cancer Research</i> , 2015, 17, 133.	2.2	21
125	Modified aesthetic abdominoplasty approach in perforator free-flap breast reconstruction: Impact of drain free donor site on patient outcomes. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2015, 68, 800-809.	0.5	29
126	Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1119-1127.	0.8	36



#	ARTICLE	IF	CITATIONS
127	Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3386-3393.	0.8	180
128	Enhanced recovery after surgery in microvascular breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2015, 68, 395-402.	0.5	178
129	Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 701-708.	0.8	171
130	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors $\leq$ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2600-2608.	0.8	91
131	Three-dimensional CT angiography assessment of the impact of the dermis and the subdermal plexus in DIEP flap perfusion. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2015, 68, 525-530.	0.5	25
132	Tu1795 A Multicenter Randomized Controlled Trial to Comparing Pancreatic Leaks With Enhanced Dissection vs. Enhanced Stapling After Distal Pancreatectomy. <i>Gastroenterology</i> , 2015, 148, S-1184.	0.6	0
133	Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv369.	3.0	102
134	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
135	Abstract P2-01-02: Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy – Results from a prospective trial – ACOSOG Z1071 (Alliance). <i>Cancer Research</i> , 2015, 75, P2-01-02-P2-01-02.	0.4	18
136	Abstract P5-15-07: Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance]. , 2015, , .		1
137	Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit. <i>Cancer Research</i> , 2015, 75, S1-06-S1-06.	0.4	19
138	Folate Receptor-1 (FOLR1) Expression and Function in Triple Negative Tumors. <i>PLoS ONE</i> , 2015, 10, e0122209.	1.1	103
139	Biomarker-based trials in neuro-oncology. <i>Chinese Clinical Oncology</i> , 2015, 4, 38.	0.4	0
140	Impact of imaging measurements on response assessment in glioblastoma clinical trials. <i>Neuro-Oncology</i> , 2014, 16, vii24-vii35.	0.6	32
141	Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3600-3606.	0.8	323
142	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014, 16, vii36-vii47.	0.6	41
143	Randomized Trial of Drain Antisepsis After Mastectomy and Immediate Prosthetic Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2014, 21, 3240-3248.	0.7	13
144	Surgical Treatment of Borderline and Malignant Phyllodes Tumors: The Effect of the Extent of Resection and Tumor Characteristics on Patient Outcome. <i>Annals of Surgical Oncology</i> , 2014, 21, 3304-3309.	0.7	79

#	ARTICLE	IF	CITATIONS
145	Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 and CALGB 361004 (Alliance). <i>Journal of Oncology Practice</i> , 2014, 10, e285-e292.	2.5	65
146	Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgery</i> , 2014, 260, 608-616.	2.1	327
147	927 The Impact of Elevated Liver Enzymes and Other Patient Characteristics on 30-Day Post-Operative Major Adverse Cardiac Events: An ACS-NSQIP Analysis. <i>Gastroenterology</i> , 2014, 146, S-930.	0.6	0
148	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. <i>Cancer</i> , 2014, 120, 2325-2333.	2.0	65
149	Accuracy of Fluorodeoxyglucose-Positron Emission Tomography Within the Clinical Practice of the American College of Surgeons Oncology Group Z4031 Trial to Diagnose Clinical Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1142-1148.	0.7	38
150	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1563-1570.	0.8	252
151	Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2013, 62, 610-616.	1.2	476
152	2130 VALIDATION OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH HIGH RISK PATHOLOGICAL FEATURES POST-PROSTATECTOMY. <i>Journal of Urology</i> , 2013, 189, .	0.2	2
153	Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. <i>Neuro-Oncology</i> , 2013, 15, 735-746.	0.6	22
154	Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 607-616.	1.1	25
155	Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. <i>Journal of Urology</i> , 2013, 190, 2047-2053.	0.2	280
156	Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations. <i>Clinical Sarcoma Research</i> , 2013, 3, 12.	2.3	10
157	Achieving the Right Volume of Randomized Controlled Trials. <i>Annals of Surgery</i> , 2013, 258, 208-209.	2.1	3
158	Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. <i>Annals of Surgery</i> , 2013, 258, 422-429.	2.1	150
159	Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. <i>Cancer</i> , 2013, 119, 2447-2454.	2.0	44
160	Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. <i>PLoS ONE</i> , 2013, 8, e66855.	1.1	524
161	Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants. <i>PLoS ONE</i> , 2013, 8, e62119.	1.1	19
162	Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 36-36.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Abstract LB-296: FDG-PET avidity negatively impacts survival in pStage I NSCLC in the ACOSOG Z4031 trial.. , 2013, , .		0
164	Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. <i>Annals of Surgery</i> , 2012, 256, 428-436.	2.1	84
165	Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. <i>Molecular Cancer</i> , 2012, 11, 32.	7.9	40
166	Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence. <i>Journal of the American College of Surgeons</i> , 2012, 215, 53-59.	0.2	141
167	Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4565-4565.	0.8	0
168	CHOD/BVAM Chemotherapy and Whole-Brain Radiotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 476-482.	0.4	16
169	Association of Occult Metastases in Sentinel Lymph Nodes and Bone Marrow With Survival Among Women With Early-Stage Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 385.	3.8	234
170	Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy. <i>Chest</i> , 2011, 139, 1124-1129.	0.4	116
171	Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) nonâ€“small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> . 2011, 141, 662-670.	0.4	660
172	Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 347-353.	0.4	146
173	Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 569.	3.8	2,529
174	Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010. <i>Annals of Surgical Oncology</i> , 2010, 17, 1989-1994.	0.7	17
175	Phase II NCCTG trial of RT+Â“irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. <i>Journal of Neuro-Oncology</i> , 2010, 99, 73-80.	1.4	8
176	Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. <i>Journal of Neuro-Oncology</i> , 2010, 100, 177-186.	1.4	48
177	Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study. <i>Clinical Trials</i> , 2010, 7, 686-695.	0.7	11
178	Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation. <i>Journal of Clinical Oncology</i> , 2010, 28, 3002-3007.	0.8	42
179	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. <i>Annals of Surgery</i> , 2010, 252, 426-433.	2.1	1,081
180	Androgen Modulation of Coregulator Expression in Prostate Cancer Cells. <i>Molecular Endocrinology</i> , 2009, 23, 572-583.	3.7	64

#	ARTICLE	IF	CITATIONS
181	Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcellâ€mediated restoration of normal human chromosome 19. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 854-864.	1.5	7
182	Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. <i>Journal of Neuro-Oncology</i> , 2009, 92, 23-31.	1.4	80
183	Effects of the 5 alphaâ€reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. <i>Prostate</i> , 2009, 69, 1730-1743.	1.2	17
184	Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. <i>Nature Genetics</i> , 2009, 41, 905-908.	9.4	456
185	284 Colorectal Cancer Despite Colonoscopy: Critical Is the Endoscopist, Not the Withdrawal Time. <i>Gastroenterology</i> , 2009, 136, A-55.	0.6	3
186	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 373, 1097-1104.	6.3	1,233
187	W1969 Colorectal Cancer Despite Colonoscopy: Estimated Size of the Truly Missed Lesions. <i>Gastroenterology</i> , 2009, 136, A-764.	0.6	0
188	A Prospective Study of Quality of Life in Adults With Newly Diagnosed High-Grade Gliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 163-168.	0.6	59
189	A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy. <i>PLoS ONE</i> , 2008, 3, e2318.	1.1	160
190	What Does PLIER Really Do?. <i>Cancer Informatics</i> , 2008, 6, 117693510800600.	0.9	23
191	Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2288-2294.	0.8	260
192	The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. <i>Neuro-Oncology</i> , 2007, 9, 29-38.	0.6	263
193	The Incidence of Ischemic Stroke in Chronic Heart Failure: A Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2007, 13, 489-496.	0.7	100
194	Elevated expressions of osteopontin and tenascin C in ascending aortic aneurysms are associated with trileaflet aortic valves as compared with bicuspid aortic valves. <i>Cardiovascular Pathology</i> , 2007, 16, 144-150.	0.7	29
195	Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. <i>Arthritis and Rheumatism</i> , 2007, 56, 820-830.	6.7	213
196	Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. <i>Prostate</i> , 2007, 67, 1111-1120.	1.2	24
197	Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 628-638.	0.6	199
198	The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: Results of the American College of Surgeons Oncology Group Z0060 trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 738-745.e1.	0.4	136

#	ARTICLE	IF	CITATIONS
199	Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. <i>Journal of Neuro-Oncology</i> , 2007, 84, 279-286.	1.4	10
200	Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response. <i>Clinical Cancer Research</i> , 2006, 12, 2264-2271.	3.2	242
201	The Incidence of Stroke after Myocardial Infarction: A Meta-Analysis. <i>American Journal of Medicine</i> , 2006, 119, 354.e1-354.e9.	0.6	124
202	Ischemic stroke after heart failure: A community-based study. <i>American Heart Journal</i> , 2006, 152, 102-109.	1.2	130
203	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1192-1199.	0.4	88
204	Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1429-1439.	0.4	48
205	Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas. <i>Journal of Neuro-Oncology</i> , 2006, 76, 283-291.	1.4	161
206	Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2006, 77, 315-320.	1.4	23
207	Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 60-67.	6.7	168
208	Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 702-716.	1.5	16
209	Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 3871-3879.	0.8	77
210	A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma. <i>Cancer Research</i> , 2006, 66, 9852-9861.	0.4	678
211	A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival. <i>Neurosurgery</i> , 2005, 57, 495-504.	0.6	186
212	Cognitive function after radiotherapy for supratentorial low-grade glioma: A North Central Cancer Treatment Group prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1175-1183.	0.4	156
213	A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1361-1367.	0.4	108
214	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 68-77.	1.5	89
215	Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. <i>Cancer</i> , 2005, 103, 2363-2372.	2.0	60
216	Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. <i>Arthritis and Rheumatism</i> , 2005, 52, 402-411.	6.7	815

#	ARTICLE	IF	CITATIONS
217	The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. <i>Arthritis and Rheumatism</i> , 2005, 52, 412-420.	6.7	398
218	Cardiovascular death in rheumatoid arthritis: A population-based study. <i>Arthritis and Rheumatism</i> , 2005, 52, 722-732.	6.7	818
219	How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. <i>Arthritis and Rheumatism</i> , 2005, 52, 3039-3044.	6.7	145
220	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	0.8	688
221	Risk Factor Implications of Incidentally Discovered Uncomplicated Bundle Branch Block. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1585-1590.	1.4	32
222	Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. <i>American Heart Journal</i> , 2005, 149, 316-321.	1.2	31
223	Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 700-707.	0.9	234
224	Faster cyclic loess: normalizing RNA arrays via linear models. <i>Bioinformatics</i> , 2004, 20, 2778-2786.	1.8	178
225	Long-Term Outcome of Patients Who Received Implantable Cardioverter Defibrillators for Stable Ventricular Tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 658-664.	0.8	29
226	Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 3450-3457.	6.7	184
227	Long-term prognosis of inducible ventricular flutter: not an innocent finding. <i>American Heart Journal</i> , 2004, 147, 649-654.	1.2	17
228	Leukemic B Cells from CD38 Positive but Not CD38 Negative B-CLL Patients Express Heightened Levels of Cell Cycle Related Genes.. <i>Blood</i> , 2004, 104, 4809-4809.	0.6	1
229	Hormone replacement therapy and risk of acute myocardial infarction in postmenopausal women with diabetes mellitus. <i>American Journal of Cardiology</i> , 2003, 91, 1275-1277.	0.7	5
230	Frequency of development of idiopathic dilated cardiomyopathy among relatives of patients with idiopathic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 2003, 91, 1389-1392.	0.7	25
231	A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1169-1176.	0.4	306
232	Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. <i>Atherosclerosis</i> , 2003, 167, 205-214.	0.4	79
233	Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. <i>Atherosclerosis</i> , 2003, 168, 315-322.	0.4	46
234	Clinical predictors of exercise capacity 1 year after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 16-27.	0.3	62

#	ARTICLE	IF	CITATIONS
235	Long-Term Outcomes of Out-of-Hospital Cardiac Arrest after Successful Early Defibrillation. <i>New England Journal of Medicine</i> , 2003, 348, 2626-2633.	13.9	361
236	Gender Differences in C-Reactive Protein Concentrations - Confirmation with Two Sensitive Methods. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 56-9.	1.4	58
237	Lack of association between plasma homocysteine and angiographic coronary artery disease in the era of fortification of cereal grain flour with folic acid. <i>Atherosclerosis</i> , 2002, 165, 375-381.	0.4	17
238	Partial Normalization of the Heart Rate Response to Exercise After Cardiac Transplantation: Frequency and Relationship to Exercise Capacity. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1295-1300.	1.4	38
239	Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. <i>American Journal of Cardiology</i> , 2002, 90, 875-878.	0.7	26
240	Effect of Abciximab on the Outcome of Emergency Coronary Artery Bypass Grafting After Failed Percutaneous Coronary Intervention. <i>Mayo Clinic Proceedings</i> , 2001, 76, 784-788.	1.4	6
241	Aortic Stenosis: No More Hemodynamic Cardiac Catheterization!. <i>Mayo Clinic Proceedings</i> , 2001, 76, 961.	1.4	5
242	Effect of Abciximab on the Outcome of Emergency Coronary Artery Bypass Grafting After Failed Percutaneous Coronary Intervention. <i>Mayo Clinic Proceedings</i> , 2001, 76, 784-788.	1.4	17